▲Wirig Diagram Hot
▲ ▲ ▼

Papillary Renal Cell Carcinoma Type 1 vs Type 2: Pathological Differences

By

Papillary renal cell carcinoma (PRCC) is a prevalent type of kidney cancer, accounting for approximately 10-15% of all renal cell carcinomas. It's characterized by its unique papillary architecture, where tumor cells grow in finger-like projections. But PRCC isn't one-size-fits-all; it's further classified into two main types: Type 1 and Type 2, each with distinct pathological features and behaviors. Let's delve into the differences between these two subtypes to better understand their implications for diagnosis and treatment.

The categorization of PRCC into Types 1 and 2 was established by the International Society of Urological Pathology (ISUP) in 2013. This classification is essential as it allows for more tailored predictions of patient prognosis and helps guide personalized treatment plans.

Type 1 Papillary Renal Cell Carcinoma (PRCC)

Type 1 PRCC is the more common subtype, accounting for around 60-70% of all PRCCs. It tends to occur in younger patients and is often associated with von Hippel-Lindau (VHL) disease, a hereditary cancer syndrome. Type 1 PRCCs are usually slow-growing and have a better prognosis compared to Type 2.

Impairment of MAD2B–PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas | PNAS
Impairment of MAD2B–PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas | PNAS
Renal cell Carcinoma
Renal cell Carcinoma
Renal Cell Carcinoma (RCC) & Pediatric Tumors 🎗️
Renal Cell Carcinoma (RCC) & Pediatric Tumors 🎗️

Histologically, Type 1 PRCC is characterized byExtractor papillae with foamy macrophages, psammoma bodies, and sparse_stromal cells. The tumor cells themselves have voluminous cytoplasm, eosinophilic or clear cytoplasm, and low nuclear grade.

Histological Features of Type 1 PRCC

Type 1 PRCCs often display prominent papillae with finger-like projections into dilated cystic spaces. The papillary cores are typically fibro-vascular, with aفًاdstromal cells and numerous foamy macrophages. Psammoma bodies, which are calcified structures, are often present and can aid in diagnosis.

Renal Cell Carcinoma
Renal Cell Carcinoma
an x - ray shows the location of the diaper in the lower part of the abdomen
an x - ray shows the location of the diaper in the lower part of the abdomen
A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population - Nature Communications
A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population - Nature Communications

The tumor cells themselves have varying appearances. They can have eosinophilic, pale, or clear cytoplasm. Regardless of the cytoplasm's appearance, the nuclei are usually small and hyperchromatic, indicating a low nuclear grade. Mitotic activity is typically low in Type 1 PRCCs.

Molecular Features of Type 1 PRCC

At the genetic level, Type 1 PRCCs frequently exhibit inactivation of the VHL gene, often due to truncating mutations. This gene is a tumor suppressor that plays a crucial role in regulating Cellular oxygen levels and is part of the REACT pathway. Inactivation of VHL leads to overexpression of hypoxia-inducible factors, driving tumor growth.

Type 1 PRCCs also commonly have activating mutations in the C मेueva amino/gene, which encodes for the met proto-oncogene, a tyrosine kinase receptor. These mutations result in constitutive activation of the Met signaling pathway, further promoting tumor growth and proliferation.

Papillary Renal Cell Carcinoma (RCC) Left Kidney and Hepatic Hemangioma
Papillary Renal Cell Carcinoma (RCC) Left Kidney and Hepatic Hemangioma
purple and white blood cells are shown in four separate images, each with different colors
purple and white blood cells are shown in four separate images, each with different colors
Malignant Tumors of the Kidney
Malignant Tumors of the Kidney
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy - British Journal of Cancer
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy - British Journal of Cancer
The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis | PNAS
The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis | PNAS
Chromophobe
Chromophobe

Type 2 Papillary Renal Cell Carcinoma (PRCC)

Type 2 PRCC is less common, making up around 25-35% of all PRCCs. It typically occurs in older patients and has a worse prognosis compared to Type 1. Type 2 PRCCs tend to be more aggressive and are often associated with chromophobe renal cell carcinoma.

Histologically, Type 2 PRCC is characterized by fino papillae with hyaline terminals, and the tumor cells have hobnail or continuous pavement-like arrangements. The nuclei are larger and more pleomorphic than those in Type 1 PRCC.

Compared to Type 1 PRCC, the management strategies and prognosis of Type 2 PRCC are currently less well understood. However, ongoing research is working to unravel the unique characteristics of this subtype to improve patient outcomes.

Papillary Left Renal Cell Carcinoma
Papillary Left Renal Cell Carcinoma
Sample Pages for Advanced Renal Cell Carcinoma
Sample Pages for Advanced Renal Cell Carcinoma

Histological Features of Type 2 PRCC

Type 2 PRCCs typically have finer papillae than Type 1. The cores of these papillae are composed of basophilic, hyperchromatic tumor cells arranged in a continuous pavement-like or hobnail pattern. Hyaline material can be seen at the tips of the papillae.

The tumor cells in Type 2 PRCC have distinct histological features. They usually have eosinophilic cytoplasm with small, round nuclei in a nested or tubular growth pattern. However, some variants may demonstrate clear cytoplasm and more pleomorphic nuclei. Mitotic activity is often higher in Type 2 compared to Type 1 PRCCs.

Molecular Features of Type 2 PRCC

The molecular profile of Type 2 PRCC is quite different from Type 1. It often exhibits mosaic losses of chromosomes 1 and 4, as well as gains of chromosomes 7, 16, and 17. Activation of the AKT-mTOR pathway is also common, which can drive cell proliferation and survival.

Genetic alterations in the huntingtin-interacting protein 1 (HIP1) gene have also been identified in some Type 2 PRCCs. These alterations can lead to increased cell proliferation and invasion, contributing to the more aggressive behavior of this subtype.

Understanding the difference between Type 1 and Type 2 papillary renal cell carcinoma is crucial for optimal patient management. With ongoing research, the unique pathological features and molecular characteristics of these subtypes are being unraveled, allowing for more personalized treatment plans and improved patient outcomes. It's an exciting time for the field of urology, and with each new discovery, we're one step closer to conquering this complex disease.

💬 Comments ↗ Share ★ Save
AD